The Potential Role of sPD-L1 as a Predictive Biomarker in EGFR-Positive Non-Small-Cell Lung Cancer [PDF]
Current Issues in Molecular BiologyBackground/Objectives: A significant breakthrough in non-small-cell lung cancer (NSCLC) treatment has occurred with the introduction of targeted therapies and immunotherapy.
Vesna Ćeriman Krstić +12 more
doaj +6 more sources
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases [PDF]
Cancers, 2021 International audienceUpon T-cell receptor stimulation, the Programmed cell Death-1 receptor (PD-1) expressed on T-cells can interact with its ligand PD-L1 expressed at the surface of cancer cells or antigen-presenting cells.
Xavier Thuru +5 more
core +6 more sources
Circulating sPD-L1 as a tumor microenvironment-derived biomarker: enhancing diagnostic discrimination accuracy in breast cancer [PDF]
Cancer Immunology, ImmunotherapyProgrammed cell death ligand 1 (PD-L1) plays a pivotal role in breast cancer immune evasion, yet tissue-based detection suffers from invasiveness and spatial heterogeneity.
Yue Zhang +4 more
doaj +4 more sources
Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer [PDF]
Journal of Medical Biochemistry, 2019 Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung ...
Mirkov, Damjan +15 more
core +8 more sources
The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer [PDF]
Frontiers in Oncology, 2022 Colorectal cancer (CRC) is one of the most significant neoplasms with high morbidity and mortality. Activation of the programmed death protein 1/programmed death ligand 1 (PD-1/PD-L1) signaling pathway results in tumor immune evasion by suppressing the ...
Weifang Shao +5 more
doaj +4 more sources
Linchuang shenzangbing zazhi, 2020 Objective To investigate expression and its clinical significance of soluble programmed death protein 1(sPD-1) and soluble programmed death ligand 1(sPD-L1) in patients with primary nephrotic syndrome(PNS).Methods A total of 87 PNS patients admitted to ...
LV Zhi-an, WANG Juan-ni, YANG Yan-yan
doaj +2 more sources
Effects of Apatinib combined with Temozolomide on levels of sPD-1 and sPD-L1 in patients with drug-resistant recurrent glioblastoma [PDF]
ClinicsObjective: This study aimed to explore the effects of Apatinib combined with Temozolomide (TMZ) on the levels of Soluble PD-1 (sPD-1) and Soluble Programmed Death-1 Ligand (sPD-L1) in patients with drug-resistant recurrent Glioblastoma (GB). Study design:
Tang, Xiao Ping +3 more
core +5 more sources
Association of plasma sPD‐1 and sPD‐L1 with disease status and future relapse in AQP4‐IgG (+) NMOSD [PDF]
Annals of Clinical and Translational Neurology, 2023 Objective Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune‐mediated disorder with aquaporin 4‐immunoglobulin G (AQP4‐IgG) in most settings. Soluble programmed death‐1 (sPD‐1) and soluble programmed death ligand 1 (sPD‐L1) play key roles in
Jia Liu +8 more
doaj +4 more sources
Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs) [PDF]
Cancer Immunology, ImmunotherapyIntroduction There is a need for biomarkers to predict response and survival to immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC). Soluble PD-L1 (sPD-L1) has shown biomarker potential.
Adrien Costantini +5 more
doaj +3 more sources
Coatings, 2023 Soluble programmed death-ligand 1 (sPD-L1) levels vary widely among different stages of tumor development, so the direct quantification of sPD-L1 as a cancer biomarker is useful in cancer diagnosis, prognosis and therapeutic assessment.
Yuyan Peng +3 more
core +2 more sources